Since commencing his legal practice in 2018, he has handled a string of landmark IP cases at courts of all levels, including the ticagrelor compound patent ownership confirmation case, the ticagrelor crystal form patent ownership confirmation case, the civil-administrative cross-case involving infringement and ownership confirmation of the levornidazole pharmaceutical invention patent, three pharmaceutical patent linkage litigation cases and three administrative ruling cases for Company An X, the Qualcomm v. Apple invention patent infringement dispute, a series of standard essential patent licensing disputes between Sharp & OPPO, Sharp & vivo, Sharp & Xiaomi, as well as the "fence post" invention patent infringement case, among others.

His representative cases include: 1 case listed in the Top 10 Intellectual Property Cases of Chinese Courts (2020); 2 cases selected as 50 Model Intellectual Property Cases of Chinese Courts (2018, 2022); 1 case included in the Gazette of the Supreme People’s Court (2022); 1 case named a Model Case by the IP Tribunal of the Supreme People’s Court (2022); 4 cases shortlisted for the 100 Model Cases marking the fifth anniversary of the establishment of the IP Tribunal of the Supreme People’s Court; and 2 cases honored as Outstanding Deals & Cases by China Business Law Journal (2019, 2021).

He has authored four monographs including A Detailed Interpretation of China’s Patent Litigation, published over ten academic papers in core journals and dozens of professional articles on electronic media platforms.